Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study

被引:10
作者
Wu, Mengjing [1 ,2 ]
Zhu, Yunyun [1 ,2 ]
Chen, Xiancheng [3 ]
Wang, Xinpeng [1 ,2 ]
Lin, Xinyue [1 ,2 ]
Yan, Xue [1 ,2 ]
Mo, Peng [1 ,2 ]
Ye, Ying [1 ,2 ]
Zeng, Yanjing [1 ,2 ]
Yang, Yanyong [4 ]
Fu, Zhichao [1 ,2 ]
机构
[1] Fujian Med Univ, Hosp Joint Logist Team 900, Dept Radiotherapy, Fuzhou, Peoples R China
[2] Xiamen Univ, Dongfang Hosp, Sch Med, Dept Radiotherapy, Xiamen, Peoples R China
[3] Guangqian Hosp, Dept Radiotherapy, Quanzhou, Peoples R China
[4] Naval Med Univ, Fac Naval Med, Dept Radiat Med, 800 Xiangyin Rd, Shanghai 200433, Peoples R China
关键词
Advanced esophageal cancer; immunotherapy; biomarker; prognostic nutritional index; CHEMOTHERAPY; OUTCOMES; THERAPY;
D O I
10.21037/jgo-23-48
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune checkpoint inhibitors (ICIs) play an important role in the treatment of esophageal cancer (EC). However, their efficacy is variable, and there are still no effective and convenient biomarkers to identify and assess their efficacy. In recent years, programmed cell death-ligand 1 (PD-L1) expression, tumor mutation burden (TMB) and other commonly used biomarkers still cannot meet clinical needs. PNI is easy to obtain and its predictive value for the prognosis of immunotherapy has been confirmed in many cancer species, but the relationship between PNI and the efficacy of immunotherapy for esophageal cancer is still unclear. Therefore, this study aims to explore the predictive value of PNI in advanced esophageal cancer treated with ICIs. Methods: The clinicopathological features of 78 patients with advanced EC who received immunotherapy in the 900th Hospital of the Joint Logistics Team from September 2018 to May 2022 were retrospectively analyzed. The laboratory test results within 10 days prior to the start of ICI treatment were recorded, including absolute lymphocyte count and albumin (ALB) level. Meanwhile, the effects of pre-treatment prognostic nutritional index (PNI) and body mass index (BMI) on the overall survival (OS) and progression-free survival (PFS) in patients with advanced EC were analyzed. Results: The median age of the enrolled patients was 58 years, and 38 patients (48.7%) received second-or-later-line therapy. The median progression-free survival (mPFS) and median overall survival (mOS) were 7.4 months and 13 months, respectively. The mPFS and mOS were 8.8 months and 15 months, respectively, in the high baseline PNI subgroup, which were significantly higher than those in the low baseline PNI subgroup (4.7 and 8.2 months, respectively; both P<0.05). Multivariate regression analysis showed that low baseline PNI was an independent predictor of poor PFS [hazard studio (HR) =0.35, 95% CI: 0.14-0.85, P=0.020) and poor OS (HR =0.41, 95% CI: 0.17-0.99, P=0.047) and treatment line was an independent predictor of PFS. Baseline BMI was not significantly associated with prognosis. Conclusions: PNI is a simple and effective biomarker for predicting the prognosis of immunotherapy in patients with advanced EC, although further prospective studies are warranted.
引用
收藏
页码:54 / 63
页数:10
相关论文
共 50 条
[31]   Prognostic significance of prognostic nutritional index and systemic immune‐inflammation index in patients after curative breast cancer resection: a retrospective cohort study [J].
Tai Xu ;
Si-Ming Zhang ;
He-Ming Wu ;
Xiao-Min Wen ;
Dong-Qin Qiu ;
Yu-Yang Yang ;
Li-Zhen Wang ;
Wen-Biao Zhu ;
Li-Shan He ;
Jian-Juan Li .
BMC Cancer, 22
[32]   Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study [J].
Li, Xiaoyan ;
Lu, Di ;
Zhang, Zhibo ;
Zhang, Yuning ;
Wang, Jinliang ;
Hu, Yi .
JOURNAL OF THORACIC DISEASE, 2022, 14 (10) :4125-4135
[33]   New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors [J].
Bamias, Aristotelis ;
Merseburger, Axel ;
Loriot, Yohann ;
James, Nicholas ;
Choy, Ernest ;
Castellano, Daniel ;
Lopez-Rios, F. ;
Calabro, Fabio ;
Kramer, Mario ;
de Velasco, Guillermo ;
Zakopoulou, Roubini ;
Tzannis, Kimon ;
Sternberg, Cora N. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
[34]   Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors [J].
Stukalin, Igor ;
Navani, Vishal ;
Gupta, Mehul ;
Ruan, Yibing ;
Boyne, Devon J. ;
O'Sullivan, Dylan E. ;
Meyers, Daniel E. ;
Goutam, Siddhartha ;
Sander, Michael ;
Ewanchuk, Benjamin W. ;
Brenner, Darren R. ;
Suo, Aleksi ;
Cheung, Winson Y. ;
Heng, Daniel Y. C. ;
Monzon, Jose G. ;
Cheng, Tina .
ONCOLOGIST, 2023, 28 (09) :812-822
[35]   Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors [J].
Shen, Jinhai ;
Ye, Xinqi ;
Hou, Hui ;
Wang, Yun .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
[36]   Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer [J].
Tanaka, Satomi ;
Uchino, Junji ;
Yokoi, Takashi ;
Kijima, Takashi ;
Goto, Yasuhiro ;
Suga, Yoshifumi ;
Katayama, Yuki ;
Nakamura, Ryota ;
Morimoto, Kenji ;
Nakao, Akira ;
Hibino, Makoto ;
Tani, Nozomi ;
Takeda, Takayuki ;
Yamaguchi, Hiroyuki ;
Tachibana, Yusuke ;
Takumi, Chieko ;
Hiraoka, Noriya ;
Takeshita, Masafumi ;
Onoi, Keisuke ;
Chihara, Yusuke ;
Taniguchi, Ryusuke ;
Yamada, Takahiro ;
Matsui, Yohei ;
Hiranuma, Osamu ;
Morimoto, Yoshie ;
Iwasaku, Masahiro ;
Tokuda, Shinsaku ;
Kaneko, Yoshiko ;
Yamada, Tadaaki ;
Takayama, Koichi .
DIAGNOSTICS, 2022, 12 (02)
[37]   The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy [J].
Pan, Yuting ;
Ma, Yue ;
Dai, Guanghai .
NUTRIENTS, 2023, 15 (19)
[38]   A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer [J].
Chen, Zhuo ;
Zou, Zhuoling ;
Qian, Min ;
Xu, Qin ;
Xue, Guojuan ;
Yang, Juan ;
Luo, Tinglan ;
Hu, Lianjie ;
Wang, Bin .
TRANSLATIONAL ONCOLOGY, 2024, 44
[39]   Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study [J].
Xu, Tai ;
Zhang, Si-Ming ;
Wu, He-Ming ;
Wen, Xiao-Min ;
Qiu, Dong-Qin ;
Yang, Yu-Yang ;
Wang, Li-Zhen ;
Zhu, Wen-Biao ;
He, Li-Shan ;
Li, Jian-Juan .
BMC CANCER, 2022, 22 (01)
[40]   Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study [J].
Xiao, Lu-shan ;
Li, Rui-ning ;
Cui, Hao ;
Hong, Chang ;
Huang, Chao-yi ;
Li, Qi-mei ;
Hu, Cheng-yi ;
Dong, Zhong-yi ;
Zhu, Hong-bo ;
Liu, Li .
BMC CANCER, 2022, 22 (01)